Veru Announces Proposed Public Offering

Core Viewpoint - Veru Inc. has initiated an underwritten public offering of its common stock and related warrants to fund the development of its drug enobosarm, particularly for the Phase 2b PLATEAU clinical study [1][2]. Group 1: Offering Details - The public offering includes shares of common stock, pre-funded warrants, Series A warrants, and Series B warrants, all offered by Veru [1][3]. - The offering is subject to market conditions, and there is no guarantee regarding its completion or the terms [1]. - Canaccord Genuity LLC and Oppenheimer & Co. Inc. are the joint book-running managers for this offering [2]. Group 2: Use of Proceeds - The net proceeds from the offering will primarily support the Phase 2b PLATEAU clinical study activities for enobosarm [2]. - Additional proceeds will be allocated for working capital, existing vendor obligations, and general corporate purposes, including collaboration with potential development partners for enobosarm [2]. Group 3: Regulatory Information - The offering is conducted under a shelf registration statement on Form S-3, which was filed with the SEC on March 16, 2023, and declared effective on April 14, 2023 [3]. - A preliminary prospectus supplement will be filed with the SEC and will be accessible on the SEC's website [3].